<unk> -nxki is indicated for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting and for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
Trastuzumab deruxtecan
Trastuzumab emtansine
Afatinib
Loncastuximab tesirine
Trastuzumab/hyaluronidase
Neratinib
Dasatinib
Cetuximab